Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis
Year: 2021
Type: review
Abstract: BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom in 2018. METHODS: The socioeconomic burden of diagnosed NASH was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on a literature review, databases and consultation with clinical experts, economists and patient groups. RESULTS: The proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8%-39.1% for advanced fibrosis (F3-F4 compensated cirrhosis). Total economic costs were €8548-19 546M. Of these, health system costs were €619-1292M. Total wellbeing costs were €41 536-90 379M. The majority of the undiagnosed population (87.3%-88.2% of total prevalence) was found to have early-stage NASH, which, left untreated, may progress to more resource consuming ESLD over time. CONCLUSIONS: This study found that the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.
Source: Liver International
DOI: 10.1111/liv.14825
Authors: Jörn M. Schattenberg, Jeffrey V. Lazarus, Philip N. Newsome, Lawrence Serfaty, Alessio Aghemo, Salvador Augustin, Emmanuel Tsochatzis, Victor de Ledinghen, Elisabetta Bugianesi, Manuel Romero‐Gomez, Heike Bantel, Stephen D. Ryder, Jerome Boursier, Vincent Leroy, Javier Crespo, Laurent Castera, Lefteris Floros, Vincenzo Atella, Jorge Mestre‐Ferrandiz, Rachel Elliott, Achim Kautz, Alice Morgan, Sally L. Sansom, Sharad Vasudevan, Lynne Pezzullo, Aldo Trylesinski, Sandrine Cure, Victoria Higgins, Vlad Ratziu
Institutions: University Medical Center of the Johannes Gutenberg University Mainz, Barcelona Institute for Global Health, Universitat de Barcelona, University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Hôpitaux Universitaires de Strasbourg, Humanitas University, IRCCS Humanitas Research Hospital, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, The Royal Free Hospital, University College London, Centre Hospitalier Universitaire de Bordeaux, University of Turin, Hospital Universitario Virgen del Rocío, Medizinische Hochschule Hannover, University of Nottingham, National Institute for Health and Care Research, Nottingham Biomedical Research Centre, Université d'Angers, Centre Hospitalier Universitaire de Grenoble, Marqués de Valdecilla University Hospital, Hôpital Beaujon, University of Rome Tor Vergata, University of Manchester, Intercept Pharmaceuticals (United States), Adelphi Group (United Kingdom), Pitié-Salpêtrière Hospital
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,100
Funder: Intercept Pharmaceuticals
OpenAlex ID: W3133101076
